2,4-dibenzylglutaric acid ethyl monoester | 105129-29-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2,4-dibenzylglutaric acid ethyl monoester
• 英文别名: 4-ethoxycarbonyl(S,S)-2,4-dibenzylbutyric acid；(2S,4S)-2,4-dibenzyl-5-ethoxy-5-oxopentanoic acid
• CAS: 105129-29-1
• 化学式: C₂₁H₂₄O₄
• 分子量: 340.419
• InChiKey: JRQLTSJWCGKDDN-RTBURBONSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-dibenzylglutaric acid ethyl monoester 在 palladium on activated charcoal 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 18.0h， 生成 N-<(SR,SR)-2,4-dibenzyl-4-carbethoxybutyryl>-β-alanine
  参考文献：
  名称：

  Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives

  摘要：

  The synthesis of two new series of dicarboxylic acid dipeptides and two sulfhydryl-containing inhibitors are described. The in vitro enkephalinase inhibition data and some in vivo analgesic data are presented for these compounds. For the dibenzylglutaric acid series structure-activity relationships and in vivo analgesic activity are discussed. The reverse amides, i.e., 4-amino-2,4-dibenzylbutyric acid derivatives, are also discussed. Two sulfhydryl-containing inhibitors showed good in vivo potency in the mouse jump-latency hot-plate test after peripheral administration at moderate low doses.

  DOI：

  10.1021/jm00132a005
• 作为产物：
  描述：

  cis-2,4-dibenzylglutaric anhydride 在 三乙胺 作用下， 以 甲苯 为溶剂， 反应 16.25h， 生成 2,4-dibenzylglutaric acid ethyl monoester
  参考文献：
  名称：

  Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives

  摘要：

  The synthesis of two new series of dicarboxylic acid dipeptides and two sulfhydryl-containing inhibitors are described. The in vitro enkephalinase inhibition data and some in vivo analgesic data are presented for these compounds. For the dibenzylglutaric acid series structure-activity relationships and in vivo analgesic activity are discussed. The reverse amides, i.e., 4-amino-2,4-dibenzylbutyric acid derivatives, are also discussed. Two sulfhydryl-containing inhibitors showed good in vivo potency in the mouse jump-latency hot-plate test after peripheral administration at moderate low doses.

  DOI：

  10.1021/jm00132a005

文献信息

• Certain n-substituted butyramide derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05166212A1

  公开（公告）日：1992-11-24

  Disclosed are compound of the formula ##STR1## wherein X and Y independently represent hydroxymethyl; cyano; carboxy; functionally modified carboxy selected from esterified carboxy, carbamoyl, and N-substituted carbamoyl; 5-tetrazolyl; 2-oxazolyl, 4,5-dihydro-2-oxazolyl, or each said grouping substituted by lower alkyl; R and R.sub.o independently represent lower alkyl, (C.sub.3 -C.sub.7)-cycloalkyl-lower alkyl, or aryl-lower alkyl; A represents methylene; or A represents methylene substituted by lower alkyl, by lower alkylthio-lower alkyl, by aryl-lower alkylthio-lower alkyl, by arylthio-lower alkyl, by hydroxy-lower alkyl, by acyloxy-lower alkyl, by lower alkoxy-lower alkyl, by alkyloxy-lower alkyl, by aryloxy-lower alkyl, by amino-lower alkyl by acylamino-lower alkyl, by guanidino-lower amino-lower alkyl, by (C.sub.3 -C.sub.7)-cycloalkyl, by (C.sub.3 -C.sub.7)-cycloalkyl-lower alkyl, by aryl or aryl-lower alkyl; pharmaceutically acceptable ester and amide derivatives of any said compounds having a free carboxy group; pharmaceutically acceptable salts; methods for synthesis; pharmaceutical compositions thereof; and use thereof as endopentidase inhibitors.

  本发明涉及一种化合物，其化学式为##STR1##其中X和Y独立地表示羟甲基;氰基;羧基;功能修饰的羧基，所述功能修饰的羧基选自酯化羧基，氨基甲酰基和N-取代氨基甲酰基; 5-四唑基; 2-噁唑基，4,5-二氢-2-噁唑基，或每个所述基团均被低烷基取代; R和R.sub.o独立地表示低烷基，(C.sub.3-C.sub.7)-环烷基-低烷基或芳基-低烷基; A表示亚甲基; 或A表示被低烷基，被低烷硫基-低烷基，被芳基-低烷硫基-低烷基，被芳基硫基-低烷基，羟基-低烷基，酰氧基-低烷基，低烷氧基-低烷基，烷氧基-低烷基，芳氧基-低烷基，氨基-低烷基，酰胺基-低烷基，鸟氨酸基-低氨基-低烷基，(C.sub.3-C.sub.7)-环烷基，(C.sub.3-C.sub.7)-环烷基-低烷基，芳基或芳基-低烷基取代的亚甲基取代; 具有自由羧基的任何所述化合物的药学上可接受的酯和酰胺衍生物; 药学上可接受的盐; 合成方法; 其药物组成物; 以及作为内肽酶抑制剂的用途。
• Certain N-substituted butyramide derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05021430A1

  公开（公告）日：1991-06-04

  Disclosed are compound of the formula ##STR1## wherein X and Y independently represent hydroxymethyl; cyano; carboxy; functionally modified carboxy selected from esterified carboxy, carbamoyl, and N-substituted carbamoyl; 5-tetrazolyl; 2-oxazolyl, 4,5-dihydro-2-oxazolyl, or each said grouping substituted by lower alkyl; R and R.sub.o independently represent lower alkyl, (C.sub.3 -C.sub.7)-cycloalkyl-lower alkyl, or aryl-lower alkyl; A represents methylene; or A represents methylene substituted by lower alkyl, by lower alkylthio-lower alkyl, by aryl-lower alkylthio-lower alkyl, by arylthio-lower alkyl, by hydroxy-lower alkyl, by acyloxy-lower alkyl, by lower alkoxy-lower alkyl, by aryl-lower alkyloxy-lower alkyl, by aryloxy-lower alkyl, by amino-lower alkyl, by acylamino-lower alkyl, by guanidino-lower alkyl, by (C.sub.3 -C.sub.7)-cycloalkyl, by (C.sub.3 -C.sub.7)-cycloalkyl-lower alkyl, by aryl or aryl-lower alkyl; pharmaceutically acceptable ester and amide derivatives of any said compounds having a free carboxy group; pharmaceutically acceptable salts; methods for synthesis; pharmaceutical compositions thereof; and use thereof as endopeptidase inhibitors.

  本发明涉及一种化合物，其化学式为##STR1##其中X和Y独立地表示羟甲基;氰基;羧基;功能修饰的羧基，所述功能修饰的羧基被选择为酯化羧基，氨基甲酰基或N-取代氨基甲酰基;5-四唑基;2-噁唑基，4,5-二氢-2-噁唑基，或所述各分组被低烷基取代;R和R.sub.o独立地表示低烷基，(C.sub.3-C.sub.7)环烷基-低烷基，或芳基-低烷基;A表示亚甲基;或A表示被低烷基，被低烷基硫醚-低烷基，被芳基-低烷基硫醚-低烷基，被芳基硫醚-低烷基，被羟基-低烷基，被酰氧基-低烷基，被低烷氧基-低烷基，被芳基-低烷氧基-低烷基，被芳氧基-低烷基，被氨基-低烷基，被酰胺基-低烷基，被鸟氨基-低烷基，被(C.sub.3-C.sub.7)环烷基，被(C.sub.3-C.sub.7)环烷基-低烷基，被芳基或芳基-低烷基取代;具有自由羧基的任何所述化合物的药学上可接受的酯和酰胺衍生物;药学上可接受的盐;其合成方法;其制药组合物;以及作为内肽酶抑制剂的用途。
• US5021430A
  申请人：——

  公开号：US5021430A

  公开（公告）日：1991-06-04
• US5166212A
  申请人：——

  公开号：US5166212A

  公开（公告）日：1992-11-24
• Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives
  作者：Gary M. Ksander、Clive G. Diefenbacher、Andrew M. Yuan、F. Clark、Yumi Sakane、R. D. Ghai

  DOI：10.1021/jm00132a005

  日期：1989.12

  The synthesis of two new series of dicarboxylic acid dipeptides and two sulfhydryl-containing inhibitors are described. The in vitro enkephalinase inhibition data and some in vivo analgesic data are presented for these compounds. For the dibenzylglutaric acid series structure-activity relationships and in vivo analgesic activity are discussed. The reverse amides, i.e., 4-amino-2,4-dibenzylbutyric acid derivatives, are also discussed. Two sulfhydryl-containing inhibitors showed good in vivo potency in the mouse jump-latency hot-plate test after peripheral administration at moderate low doses.